Beyond PAK, other signaling mechanisms downstream of NF2 loss such as the Hippo pathway41, the Rho/Rac/Cdc42 family of small GTPases42, or IRF-mediated apoptosis43 may also be candidates for combination molecular therapy to treat neurofibromatosis-associated tumors. The gene discussed is CDC42; the disease is neurofibromatosis.